Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAK683 in Advanced Malignancies
NCT02900651Phase 1Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label, single-arm trial of MAK683 in diffuse large B-cell lymphoma (DLBCL), nasopharyngeal carcinoma (NPC), gastric cancer (GC) and 3 more, sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Safety and tolerability at 3 years. Started Oct 2016; status: terminated.
02
Drugs
MAK683
03
Conditions
diffuse large B-cell lymphoma (DLBCL)nasopharyngeal carcinoma (NPC)gastric cancer (GC)ovarian clear cell carcinoma (OCCC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02900651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900651.